China’s State Administration for Market Regulation (SAMR) announced on December 26, 2025, a comprehensive standardization initiative targeting the completion of over 1,800 national standard revisions and new formulations in 2026. This effort places strong emphasis on mandatory standards in high-risk and export-sensitive sectors—including medical sterilization equipment, battery recycling, and special equipment—signaling a tightening regulatory alignment with international safety frameworks, particularly for medical electrical devices.

Event Overview

SAMR stated on December 26, 2025, that it will advance more than 1,800 national standard revisions and new developments in 2026. Key priorities include mandatory national standards for medical sterilization equipment and power battery recycling, as well as the accelerated conversion of GB 9706.1–2026 (General Requirements for Basic Safety and Essential Performance of Medical Electrical Equipment) and its supporting collateral standards. These updates directly affect conformity pathways for X-ray systems, CT cooling units, and ethylene oxide sterilization cabinets exported to markets requiring CE marking or IEC 60601-1 compliance.

Industries Affected

Direct Exporters and Trading Enterprises: Companies exporting medical imaging or sterilization equipment to the EU, UK, or other IEC 60601-1–referenced markets face revised technical documentation and testing requirements. Since GB 9706.1–2026 adopts substantial harmonization with the third edition of IEC 60601-1, pre-market conformity assessments must now reflect updated risk management, usability, and essential performance verification—potentially extending time-to-market and increasing third-party certification costs.

Raw Material and Component Suppliers: Suppliers of critical subsystems—such as high-voltage generators for X-ray tubes, thermal control modules for CT cooling systems, or gas-sealing components for EO sterilizers—must ensure traceable compliance with newly referenced material biocompatibility, flammability, and electromagnetic compatibility (EMC) clauses under the revised standards. Contractual specifications may need renegotiation to reflect updated safety classification thresholds.

Manufacturing Enterprises: OEMs and contract manufacturers producing Class II/III medical electrical devices must re-evaluate design history files, perform gap analyses against GB 9706.1–2026, and update internal quality management systems (e.g., ISO 13485:2016) to integrate new essential performance verification protocols. Notably, the revised standard introduces stricter requirements for programmable electrical medical systems (PEMS), affecting firmware validation workflows.

Supply Chain Service Providers: Regulatory consultants, testing laboratories, and Notified Body representatives operating in China must align their service offerings with the updated GB 9706 series timelines. Capacity constraints are anticipated for EMC and mechanical safety testing facilities certified under CNAS, especially for multi-part collateral standard evaluations (e.g., GB 9706.2–XX sub-standards).

Key Considerations and Recommended Actions

Review Existing Product Documentation Against GB 9706.1–2026

Manufacturers should initiate side-by-side comparisons between current technical files and the final text of GB 9706.1–2026 (expected public release in Q1 2026), focusing on clauses related to risk management (Clause 4), essential performance (Clause 202), and software lifecycle controls (Annex C). Early identification of deviations supports phased implementation planning.

Prioritize Collateral Standard Alignment for High-Volume Export Products

Given the direct linkage between GB 9706.1–2026 and product-specific collateral standards (e.g., GB 9706.2–62 for CT equipment, GB 9706.2–55 for sterilization systems), exporters should map existing models to applicable sub-standards and schedule pre-assessment testing with accredited labs before mandatory enforcement dates.

Engage Early with Domestic Certification Bodies on Transition Pathways

As SAMR mandates phased adoption, enterprises should consult with CNCA-accredited certification bodies (e.g., CQC, SGS China, BV) regarding transitional arrangements—especially whether legacy test reports under GB 9706.1–2007 or GB 9706.1–2013 remain acceptable for minor design changes during the 2026–2027 transition window.

Editorial Insight / Industry Observation

Observably, this is not merely a technical update but a strategic regulatory pivot: SAMR is using mandatory standard revision as a lever to consolidate domestic manufacturing quality, reduce post-market safety incidents, and strengthen China’s influence in global medical device standard-setting forums. Analysis shows that the pace of GB 9706.1–2026 rollout exceeds previous cycles—suggesting coordinated pressure from both domestic health authorities and export market feedback. From an industry perspective, the acceleration reflects growing recognition that regulatory convergence, rather than divergence, better serves long-term competitiveness for Chinese medtech firms.

Conclusion

The 2026 standardization push represents a structural inflection point—not just for compliance departments, but for R&D strategy, supplier governance, and international market access planning. A rational interpretation is that SAMR’s approach prioritizes enforceability and traceability over rapid innovation flexibility; companies that treat standards as living inputs—not static checkboxes—will be better positioned to navigate both domestic regulatory expectations and global harmonization demands.

Source Attribution

Official announcement issued by the State Administration for Market Regulation (SAMR) on December 26, 2025. Text available via SAMR’s official website (www.samr.gov.cn) under ‘2026 National Standard Development Plan’. Note: Final texts of GB 9706.1–2026 and associated collateral standards are pending formal publication; stakeholders are advised to monitor SAMR’s Standardization Administration of China (SAC) portal for draft consultations and enforcement timelines.